Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient
Phase 2
Recruiting
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000007925
- Lead Sponsor
- Osaka University Clinical Research Group for Gastroenterological Study
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
Synchronous or metachronous (within 5 years) malignancies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence prediction by the NY-ESO-1 antibody titer In the stomach cancer patients, with NY-ESO-1 antibody titer positive before surgery, that has been resected radically, NY-ESO-1 antibody titer was measured. We examine The recurrence rate of the NY-ESO-1 antibody-positive case of the first year after surgery.
- Secondary Outcome Measures
Name Time Method 1. NY-ESO-1 antibody titer positive rate 2. Incidence of the NY-ESO-1 antigen expression in the gastric cancer tissue 3. Correlation between NY-ESO-1 antibody titer and prognosis 4. Correlation between expression of the NY-ESO-1 antigen and prognosis 5. Relations withNY-ESO-1 antibody titer and the effect of the chemotherapy